Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2020 · second_quarter · 2T
Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases; support for protecting research and development for novel diagnostics, treatments and vaccines.
Source: Senate LDA
H.R. 1 (tax policy including changes to corporate tax structure) Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Helping Families in Mental Health Crisis Act of 2016
Client: ALLERGAN USA, INC. · Firm: ALLERGAN USA, INC.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
Issues relating to tax moratoriums for medical devices.
Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2020 · first_quarter · Q1
Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases; support for protecting research and development for novel diagnostics, treatments and vaccines.
Issues relating to tax moratoriums for medical devices.
Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2019 · fourth_quarter · Q4
Issues relating to tax moratoriums for medical devices.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases.
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2019 · third_quarter · Q3
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
Issues relating to tax moratoriums for medical devices.
Proposals encouraging research and development and manufacturing of potentially life-saving treatments and ensuring patient access to improve quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases.
Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2019 · second_quarter · Q2
Issues relating to tax moratoriums for medical devices.
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients; issues related to Administration actions which would allow patients to save out-of-pocket expenses on their prescription drugs.
Encouraging proposals to improve access and coverage of appropriate mental health care treatment for all patients in need; proposals to encourage investments into research and development of novel treatments for diseases to improve patients' quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases.
Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Safety Act.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2019 · first_quarter · Q1
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs; advocacy for access to personalized treatment options for low income populations; supporting regulations to empower health care decisions between health care providers and patients.
Issues relating to tax moratoriums for medical devices.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food Drug and Cosmetic Act which simplify pathways to approve patent claims.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2018 · fourth_quarter · Q4
Proposals to maintain and strengthen patient access to needed prescription medicine and medical devices under the Medicare and Medicaid programs.
Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Security Act.
Advocacy of Allergans Social Contract with Patients to encourage greater access to critical innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving medical therapies.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2018 · third_quarter · Q3
Supporting proposals to strengthen the safety and integrity of the pharmaceutical supply chain. Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Security Act.
Support for proposals improving access and coverage of appropriate mental health care treatment for all patients in need. Proposals encouraging investments into research and development of novel treatments for diseases to improve the quality of life for patients. Supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines.
Proposals affecting access, coverage and reimbursements of prescription medicines and medical devices within the Medicare and Medicaid programs. Proposals improving reimbursements for anti-microbial medications to incentivize research and development of novel therapies.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2018 · second_quarter · Q2
Proposals to maintain and strengthen intellectual property protections to incentivize research and development of novel, new life-saving therapies to meet unmet medical needs. Proposals to modify the Hatch Waxman Act and the America Invents Act.
Proposals affecting access, coverage and reimbursements of prescription medicines and medical devices within the Medicare and Medicaid programs. Proposals improving reimbursements for anti-microbial medications to incentivize research and development of novel therapies.
Proposals affecting access, coverage and reimbursements of prescription medicines and medical devices within the Medicare and Medicaid programs. Supporting adequate resources for the Food and Drug Administration to fulfill its mission. Supporting proposals to strengthen the safety and integrity of the pharmaceutical supply chain. Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Security Act.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2018 · second_quarter · RA
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2018 · first_quarter · Q1
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Tax codes that ensure investment in research & development of novel treatments for patients. Potential modifications and technical corrections to Tax Cuts and Jobs Act of 2017 (P.L. 115-97).
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · fourth_quarter · Q4
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
H.R. 1 (tax policy including changes to corporate tax structure) Tax codes that ensure investment in research & development of novel treatments for patients.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · third_quarter · Q3
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · second_quarter · Q2
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2017 · first_quarter · Q1
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · 4A
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · 4A
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · third_quarter · 3A
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · fourth_quarter · Q4
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · third_quarter · Q3
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · second_quarter · Q2
Patent Reform Proposals; Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2016 · first_quarter · Q1
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
Junk Fax regulations and interpretations, and rule promulgations
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · fourth_quarter · Q4
Patent Reform Proposals; Patent Settlement Proposals.
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
ALLERGAN USA, INC. via ALLERGAN USA, INC.
2015 · third_quarter · Q3
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
Encouraging proposals to improve access and coverage of appropriate mental health care treatment for all patients in need; proposals to encourage investments into research and development of novel treatments for diseases to improve patients' quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines; promoting new therapeutic approaches to gene therapy and tissue replacement toward unmet medical needs; education regarding emerging health care concerns surrounding rare and undiagnosed diseases; support for providing incentives to encourage development of novel anti-infective treatments to counter microbial resistant diseases.
Advocacy of Allergan's Social Contract with Patients to encourage greater access to innovative medicines; support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving therapies.
Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Safety Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
Encouraging proposals to improve access and coverage of appropriate mental health care treatment for all patients in need; proposals to encourage investments into research and development of novel treatments for diseases to improve patients' quality of life; supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines.
Proposals to enhance intellectual property protections to meet unmet medical needs, notably research and development of life-saving therapies; proposals to modify the Food, Drug and Cosmetic Act which simplify pathways to approve patent claims.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Advocacy of Allergans Social Contract with Patients to encourage greater access to critical innovative medicines. Support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving medical therapies.
Supporting proposals to maintain the highest standards of drug and medical device safety and efficacy at all appropriate regulatory agencies. Supporting medically-appropriate, scientific-based standards for bioequivalence of non-biologic complex drugs. Supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines.
Potential modifications and technical corrections to the Tax Cuts and Jobs Act of 2017 (P.L. 115-97). Proposals encouraging investments into research and development of novel treatments for diseases to improve the quality of life for patients.
Proposals affecting access, coverage and reimbursements of prescription medicines and medical devices within the Medicare and Medicaid programs. Supporting adequate resources for the Food and Drug Administration to fulfill its mission. Supporting proposals to strengthen the safety and integrity of the pharmaceutical supply chain. Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Security Act.
Proposals to maintain and strengthen intellectual property protections to incentivize research and development of novel, new life-saving therapies to meet unmet medical needs. Proposals to modify the Hatch Waxman Act and the America Invents Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Supporting proposals to maintain the highest standards of drug and medical device safety and efficacy at all appropriate regulatory agencies. Supporting medically-appropriate, scientific-based standards for bioequivalence of non-biologic complex drugs. Supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines.
Advocacy of Allergans Social Contract with Patients to encourage greater access to critical innovative medicines. Support for strategic, market-based international trade policies to improve patient access and intellectual property protections of life-saving medical therapies.
Supporting proposals to strengthen the safety and integrity of the pharmaceutical supply chain. Supporting proposals to strengthen safety standards and enforcement of the Drug Quality and Security Act.
Support for proposals improving access and coverage of appropriate mental health care treatment for all patients in need. Proposals encouraging investments into research and development of novel treatments for diseases to improve the quality of life for patients. Supporting protections for patients from illegal and inappropriate exposure to counterfeit and diverted medicines.
Potential modifications and technical corrections to the Tax Cuts and Jobs Act of 2017 (P.L. 115-97). Proposals encouraging investments into research and development of novel treatments for diseases to improve the quality of life for patients.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Issues relating to the pharmaceutical industry.
Access to appropriate mental health care treatments across the U.S. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug compounding and the Drug Quality and Security Act of 2013. Drug importation/counterfeit drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Access to appropriate mental health care treatments across the U.S. Creating access to Long Acting Reversible Contraceptives for patients in areas impacted by the Zika virus. Supporting investment in safe, quality, accessible, and affordable biopharma products. Ensuring level and appropriate penalties for those harming patients by illegally diverting and counterfeiting pharmaceutical products.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals. Hatch-Waxman Implications of the Inter Partes Review Process.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding and the Drug Quality and Security Act of 2013 Drug Importation/Counterfeit Drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Medicare and Medicaid reimbursement provisions. Aligning reimbursements to allow patient access to critical medical treatments. Food and Drug Administration appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain. Ensuring the integrity of the Drug Quality and Security Act (H.R. 3204).
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues with non-biologic complex drugs. Protecting patients from illegally diverted/counterfeited medicines.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Intellectual property protections for novel therapies to treat crucial medical needs. Patent reform proposals.
Promoting the Social Contract with patients to ensure they have affordable access to critical innovative medicines. Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
Ensuring drug safety and efficacy gold standards at appropriate regulatory agency. Bioequivalence issues. Protecting patients from illegally diverted/counterfeited medicines.
Tax policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Ensuring the safety of the drug supply chain to protect patients and keep Americans safe. Drug Compounding. Drug Importation/Counterfeit Drugs.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products. Creating access to LARC's for patients in areas impacted by the Zika virus.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Patent Reform Proposals. Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.
Patent Reform Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent Reform Proposals. Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Drug Labeling Drug Importation Track and Trace
Drug safety and efficacy; bioequivalence.
Tax Policy including changes to corporate tax structure
Patent Reform Proposals; Patent Settlement Proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Medicare and Medicaid Provisions reimbursement; Agriculture, Rural Development, Food and Drug Administration Appropriations
Drug Labeling Drug Importation Track and Trace
Junk Fax regulations and interpretations, and rule promulgations
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Patent Reform Proposals; Patent Settlement Proposals.
Drug Labeling Drug Importation Track and Trace
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues
Junk Fax regulations and interpretations, and rule promulgations
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE